Pure Global AI
NCT06235983Not yet recruiting

A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors

An Open-label, Single-arm, Multicenter, Phase 1 Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Antitumor Activity of LY3537982 in Chinese Patients With KRAS G12C-Mutant Advanced Solid Tumors
Eli Lilly and CompanyPhase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
LY3537982
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Eli Lilly and Company
Location
Changsha,Changchun,Shanghai,Hangzhou,Hangzhou, China
Timeline & enrollment
Phase
Phase 1
Start date
Feb 29, 2024
End date
Apr 30, 2027
Enrollment
12 participants
Primary outcome

Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of LY3537982,PK: Area Under the Plasma Concentration Versus Time Curve (AUC) of LY3537982

Summary

This is an open-label, single-arm, multicenter, Phase 1 study of LY3537982 as monotherapy in
 Chinese participants with KRAS G12C-mutant advanced solid tumors. The main purpose of this
 study is to determine how much of LY3537982 gets into the bloodstream and how long it takes
 the body to eliminate it in Chinese participants. The safety, tolerability and preliminary
 efficacy of LY3537982 will also be evaluated. Approximately 12 patients will be enrolled in
 this study.

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06235983
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06235983 through Pure Global AI's free database. This Phase 1 trial is sponsored by Eli Lilly and Company and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 12 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.